Cambridge Investment Research Advisors Inc. raised its holdings in shares of Teleflex Incorporated (NYSE:TFX – Get Rating) by 15.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,576 shares of the medical technology company’s stock after purchasing an additional 352 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Teleflex were worth $643,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in TFX. California Public Employees Retirement System increased its position in Teleflex by 3.9% during the 4th quarter. California Public Employees Retirement System now owns 109,132 shares of the medical technology company’s stock valued at $27,243,000 after buying an additional 4,118 shares in the last quarter. Nordea Investment Management AB raised its position in shares of Teleflex by 27.9% in the 4th quarter. Nordea Investment Management AB now owns 8,832 shares of the medical technology company’s stock worth $2,201,000 after purchasing an additional 1,927 shares during the last quarter. Main Street Financial Solutions LLC boosted its stake in Teleflex by 7.2% in the 4th quarter. Main Street Financial Solutions LLC now owns 3,339 shares of the medical technology company’s stock worth $835,000 after purchasing an additional 224 shares in the last quarter. Arizona State Retirement System grew its position in Teleflex by 3.1% during the 4th quarter. Arizona State Retirement System now owns 13,276 shares of the medical technology company’s stock valued at $3,314,000 after purchasing an additional 399 shares during the last quarter. Finally, Toronto Dominion Bank increased its stake in Teleflex by 12.2% during the 4th quarter. Toronto Dominion Bank now owns 22,385 shares of the medical technology company’s stock valued at $5,584,000 after purchasing an additional 2,428 shares in the last quarter. 93.82% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other Teleflex news, Director Stuart A. Randle sold 3,021 shares of Teleflex stock in a transaction on Wednesday, May 10th. The shares were sold at an average price of $245.71, for a total value of $742,289.91. Following the sale, the director now directly owns 4,847 shares in the company, valued at approximately $1,190,956.37. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.41% of the stock is owned by company insiders.
Teleflex Stock Down 3.3 %
Teleflex (NYSE:TFX – Get Rating) last released its quarterly earnings data on Thursday, May 4th. The medical technology company reported $3.09 earnings per share for the quarter, topping analysts’ consensus estimates of $2.97 by $0.12. Teleflex had a return on equity of 15.80% and a net margin of 12.68%. The firm had revenue of $710.90 million during the quarter, compared to analyst estimates of $687.11 million. During the same quarter in the prior year, the company posted $2.88 earnings per share. The business’s quarterly revenue was up 10.8% compared to the same quarter last year. Sell-side analysts expect that Teleflex Incorporated will post 13.29 EPS for the current fiscal year.
Teleflex Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, June 15th. Stockholders of record on Monday, May 15th will be issued a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 0.57%. The ex-dividend date of this dividend is Friday, May 12th. Teleflex’s dividend payout ratio (DPR) is presently 17.73%.
Wall Street Analyst Weigh In
Several equities research analysts recently weighed in on the stock. Raymond James raised their price target on shares of Teleflex from $231.00 to $259.00 and gave the company an “outperform” rating in a research report on Friday, February 24th. Truist Financial boosted their price target on Teleflex from $250.00 to $264.00 and gave the company a “hold” rating in a research note on Monday, April 17th. Mizuho raised their price objective on shares of Teleflex from $220.00 to $250.00 in a report on Tuesday, April 18th. Wolfe Research cut shares of Teleflex from an “outperform” rating to a “peer perform” rating in a report on Wednesday, April 26th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $330.00 price target on shares of Teleflex in a research report on Thursday, March 30th. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Teleflex presently has an average rating of “Moderate Buy” and a consensus target price of $271.75.
Teleflex, Inc provides medical technology products which enables healthcare providers to improve patient outcomes and enhance patient and provider safety. The firm designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications.
- Get a free copy of the StockNews.com research report on Teleflex (TFX)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.